title: [Neoadjuvant chemotherapy with cisplatin and CPT-11 for advanced cervical cancer].
abstract: Neoadjuvant chemotherapy (NAC) is currently used for the treatment of advanced cervical cancer by many institutions. We investigated the value of NAC followed by radical surgery and/or radiotherapy for patients with locally advanced cervical cancer. Sixteen patients with stage Ib2-IIIb cervical cancer were enrolled in this study. CPT-11 (60 mg/m2) in 500 m/5% glucose was given intravenously on Days 1, 8, and 15, before cisplatin (60 mg/m2) in 500 ml normal saline. The treatment was repeated every 4 weeks for 2 or 3 cycles. All patients were evaluable for response and toxicity. Two achieved a clinical complete response (CR), 11 had a partial response (PR), 2 had no change (NC) and 1 had progressive disease (PD), for an overall response of 81.3%. Neutropenia was observed in 100% (> grade 3: 70.6%) and diarrhea was recorded in 55.9% (> grade 3: 5.9%). The combination of CPT-11 and cisplatin in locally advanced cervical cancer is thus an active regimen with a manageable toxicity as a neoadjuvant chemotherapy.
authors.affiliation: Dept. of Obstetrics and Gynecology, Kurume University, School of Medicine.
authors.forename: S
authors.initials: S
authors.lastname: Nishio
authors.forename: S
authors.initials: S
authors.lastname: Kumagai
authors.forename: N
authors.initials: N
authors.lastname: Hirai
authors.forename: Y
authors.initials: Y
authors.lastname: Tomioka
authors.forename: S
authors.initials: S
authors.lastname: Oota
authors.forename: K
authors.initials: K
authors.lastname: Fujiyoshi
authors.forename: Y
authors.initials: Y
authors.lastname: Hasuo
authors.forename: T
authors.initials: T
authors.lastname: Sugiyama
authors.forename: T
authors.initials: T
authors.lastname: Nishida
authors.forename: T
authors.initials: T
authors.lastname: Kamura
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077146:Irinotecan; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin